ASXL1 and myelodysplastic syndrome: Patients with h-MDS had significantly lower incidences of RUNX1, ASXL1, DNMT3A, EZH2, and TP53 mutations than those with NH-MDS (4.0% vs. 14.2%, P= 0.005; 7.1% vs. 21.7%, P=0.001; 3.0% vs. 12.6%, P= 0.006; 0% vs. 5.2%, P= 0.014, 3.0% vs. 10.8%, P= 0.020, respectively).